In this study, two different genetic therapies were assessed, and showed significant potential for single-dose genetic therapies to correct or silence genetic misspellings which cause hypertrophic cardiomyopathy (HCM), a disorder that increases risk for stroke as well as heart failure and affects around 1 in 500 people. Read the full paper here.
